GlassScriptPhysician profile
Mark Abi Nader
NPI 1841538147
$7,140.74
in general payments reported to CMS, 2019-2025
25 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $56.05 · 2021: $591 · 2022: $1,687 · 2023: $1,498 · 2024: $1,661 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,157 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.17 |
| Education | $321.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,071.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $808.55 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $661.81 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $629.62 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $532.33 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $519.61 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $421.98 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $365.08 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $276.51 | 2023-2025 | |
| Amgen INC. | $260.40 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Medtronic, INC. | $250.21 | 2022 | |
| Opko Pharmaceuticals, LLC | $233.44 | 2022-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $188.24 | 2021-2025 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.72 | 2023-2025 | Jardiance |
| Nxstage Medical, INC. | $134.66 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $115.05 | 2022 | |
| Glaxosmithkline, LLC. | $114.39 | 2021-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $112.58 | 2022-2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Akebia Therapeutics INC | $60.86 | 2019-2024 | Vafseo, Auryxia |
| Recor Medical INC | $51.40 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lilly USA, LLC | $44.52 | 2024 | Jardiance |
| Cormedix INC. | $27.58 | 2024 | Defencath |
| Strongbridge US INC. | $14.44 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Abi Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.